Annette Vogl

Company: Tubulis GmbH

Job title: Director, Biology & Translational Research

Seminars:

Panel Discussion – Thinking Strategically About What Targets You Select 3:30 pm

Understanding where your target choice and ADC fits into the ADC and wider oncology landscape? How do you differentiate yourself through using improved linker-payload technologies on previously validated targets? Balancing risk in your pipeline through your target choice Novel targets or previously validated targets? Discussing the role of future HER2 ADCsRead more

day: Day One

Tubutecan Platform: Technology-enabled Payload Solutions Targeting Topoisomerase-I 10:00 am

Understand how Tubulis’ P5-conjugation technology enabled rapid generation of stably linked, hydrophilic DAR8 ADCs from native antibodies Topoisomerase-I-inhibitors have become a promising payload class for ADCs in solid tumors. Tubutecans are a novel linker-payload platform for ADCs enabling the efficient and steady delivery of the TOPO-I-targeting payloads to the malignant cells Evaluate how the implementation…Read more

day: Day One